We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gene Variations Influence Risk of Prostate Cancer

By Biotechdaily staff writers
Posted on 29 Oct 2003
Researchers have found that variations in the CYP1B1 gene influence the likelihood of an individual to develop prostate cancer. More...


CYP1B1 was considered to be a candidate gene for various cancers because of its function in activating environmental procarcinogens and catalyzing the conversion of estrogens to genotoxic catechol estrogens. Investigators at Wake Forest University (Winston-Salem, NC, USA; www.wfu.edu) and Johns Hopkins University (Baltimore, MD, USA; www.jhu.edu) compared the allele, genotype, and haplotype frequencies of 13 single nucleotide polymorphisms (SNPs) of CYP1B1 among 159 hereditary prostate cancer (HPC) patients, 245 sporadic prostate cancer cases, and 222 unaffected men.

They reported in the October 20, 2003, issue of the British Journal of Cancer that one frequent haplotype (C-G-C-C-G of -1001C/T, -263G/A, -13C/T, +142C/G, and +355G/T) was associated with an increased risk for prostate cancer, while the other frequent haplotype (T-A-T-G-T) was associated with a decreased risk.

"Previous research suggests prostate cancer arises in certain individuals due to a combination of genetic and environmental factors,” explained senior author Dr. Jianfeng Xu, associate professor of cancer biology at Wake Forest University. "Our study suggests that the genetic make-up of some men leaves them more susceptible to potential carcinogens in the environment or hormones in the body that could trigger the disease.”




Related Links:
Wake Forest University
Johns Hopkins University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.